Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice

Diabetologia

Volumn 58, Issue 2, 2015, Pages 304-312

  Vinet, Laurent ^a   Lamprianou, Smaragda ^a   Babič, Andrej ^a   Lange, Norbert ^a   Thorel, Fabrizio ^a   Herrera, Pedro Luis ^a   Montet, Xavier ^b   Meda, Paolo ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Beta cell mass; Exendin; Glucagon like peptide 1 receptors; Magnetic resonance imaging; Multimodality probe; Targeted iron oxide nanoparticles

Indexed keywords

DIPHTHERIA TOXIN; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; NANOPARTICLE; GLUCAGON RECEPTOR; MOLECULAR PROBE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL LOSS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IMAGING; HELA CELL LINE; IMAGE ANALYSIS; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; FLUORESCENCE MICROSCOPY; METABOLISM; MOLECULAR PROBE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ANIMALS; FEMALE; GLUCAGON; INSULIN-SECRETING CELLS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOLECULAR PROBES; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON; TISSUE DISTRIBUTION;

EID: 84922101960     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3442-2     Document Type: Article

References (49)

1. Donath MY, Halban PA (2004) Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47:581–589
2. Andralojc K, Srinivas M, Brom M et al (2012) Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. Diabetologia 55:1247–1257
3. Virostko J, Henske J, Vinet L et al (2011) Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands. Proc Natl Acad Sci U S A 108:20719–20724
4. Derosa G, Maffioli P (2012) GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 7:214–228
5. Horsch D, Goke R, Eissele R, Michel B, Goke B (1997) Reciprocal cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islets of rat. Pancreas 14:290–294
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–2276
7. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R (2008) Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 283:11340–11347
8. Clardy SM, Keliher EJ, Mohan JF et al (2014) Fluorescent exendin-4 derivatives for pancreatic beta-cell analysis. Bioconjug Chem 25:171–177
9. Mikkola K, Yim CB, Fagerholm V et al (2014) 64Cu- and 68Ga-labelled [Nle(14), Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 16:255–263
10. Reiner T, Thurber G, Gaglia J et al (2011) Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A 108:12815–12820
11. Selvaraju RK, Velikyan I, Johansson L et al (2013) In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med 54:1458–1463
12. Pattou F, Kerr-Conte J, Wild D (2010) GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med 363:1289–1290
13. Wu Z, Liu S, Hassink M et al (2013) Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets. J Nucl Med 54:244–251
14. Wild D, Behe M, Wicki A et al (2006) [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47:2025–2033
15. Kiesewetter DO, Gao H, Ma Y et al (2012) 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging 39:463–473
16. Eriksson O, Velikyan I, Selvaraju RK et al (2014) Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab 99:1519–1524
17. Brom M, Woliner-van der Weg W, Joosten L et al (2014) Non-invasive quantification of the beta cell mass by SPECT with (111)In-labelled exendin. Diabetologia 57:950–959
18. Melis M, Vegt E, Konijnenberg MW et al (2010) Nephrotoxicity in mice after repeated imaging using 111In-labeled peptides. J Nucl Med 51:973–977
19. Vegt E, Melis M, Eek A et al (2011) Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 38:623–632
20. Antkowiak PF, Tersey SA, Carter JD et al (2009) Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging. Am J Physiol Endocrinol Metab 296:E573–E578
21. Lamprianou S, Immonen R, Nabuurs C et al (2011) High-resolution magnetic resonance imaging quantitatively detects individual pancreatic islets. Diabetes 60:2853–2860
22. Botsikas D, Terraz S, Vinet L et al (2012) Pancreatic magnetic resonance imaging after manganese injection distinguishes type 2 diabetic and normoglycemic patients. Islets 4:243–248
23. Balla DZ, Gottschalk S, Shajan G et al (2013) In vivo visualization of single native pancreatic islets in the mouse. Contrast Media Mol Imaging 8:495–504
24. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L (2006) Nanoparticle imaging of integrins on tumor cells. Neoplasia 8:214–222
25. Montet X, Weissleder R, Josephson L (2006) Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug Chem 17:905–911
26. Sun Y, Kim HS, Park J et al (2014) MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles. Theranostics 4:845–857
27. Fu W, Wojtkiewicz G, Weissleder R, Benoist C, Mathis D (2012) Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol 13:361–368
28. Perez JM, Josephson L, O'Loughlin T, Hogemann D, Weissleder R (2002) Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 20:816–820
29. Turvey SE, Swart E, Denis MC et al (2005) Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest 115:2454–2461
30. Wang P, Yoo B, Yang J et al (2014) GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging. Diabetes 63:1465–1474
31. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110
32. Nlend RN, Ait-Lounis A, Allagnat F et al (2012) Cx36 is a target of Beta2/NeuroD1, which associates with prenatal differentiation of insulin-producing beta cells. J Membr Biol 245:263–273
33. Thorel F, Nepote V, Avril I et al (2010) Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464:1149–1154
34. Klee P, Allagnat F, Pontes H et al (2011) Connexins protect mouse pancreatic beta cells against apoptosis. J Clin Invest 121:4870–4879
35. Ravier MA, Guldenagel M, Charollais A et al (2005) Loss of connexin36 channels alters beta-cell coupling, islet synchronization of glucose-induced Ca2+ and insulin oscillations, and basal insulin release. Diabetes 54:1798–1807
36. Chera S, Baronnier D, Ghila L et al (2014) Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature 514:503–507
37. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC (2010) The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release 144:10–16
38. Kirkpatrick A, Heo J, Abrol R, Goddard WA 3rd (2012) Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor. Proc Natl Acad Sci U S A 109:19988–19993
39. Pyke C, Heller RS, Kirk RK et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1290
40. Richards P, Parker HE, Adriaenssens AE et al (2014) Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63:1224–1233
41. Radermacher KA, Boutry S, Laurent S et al (2010) Iron oxide particles covered with hexapeptides targeted at phosphatidylserine as MR biomarkers of tumor cell death. Contrast Media Mol Imaging 5:258–267
42. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R (2005) Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96:327–336
43. Xu G, Kaneto H, Laybutt DR et al (2007) Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56:1551–1558
44. Eriksson O, Espes D, Selvaraju RK et al (2014) Positron emission tomography ligand [11C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes 63:3428–3437
45. Eriksson O, Selvaraju RK, Johansson L et al (2014) Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med 55:460–465
46. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717–718
47. Antkowiak PF, Vandsburger MH, Epstein FH (2012) Quantitative pancreatic beta cell MRI using manganese-enhanced Look-Locker imaging and two-site water exchange analysis. Magn Reson Med 67:1730–1739
48. Bourrinet P, Bengele HH, Bonnemain B et al (2006) Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Investig Radiol 41:313–324
49. Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A (2012) Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev 112:2323–2338